CL2018002532A1 - Composición farmacéutica que comprende empagliflozina y sus usos - Google Patents

Composición farmacéutica que comprende empagliflozina y sus usos

Info

Publication number
CL2018002532A1
CL2018002532A1 CL2018002532A CL2018002532A CL2018002532A1 CL 2018002532 A1 CL2018002532 A1 CL 2018002532A1 CL 2018002532 A CL2018002532 A CL 2018002532A CL 2018002532 A CL2018002532 A CL 2018002532A CL 2018002532 A1 CL2018002532 A1 CL 2018002532A1
Authority
CL
Chile
Prior art keywords
empagliflozin
pharmaceutical composition
hospitalization
risk
methods
Prior art date
Application number
CL2018002532A
Other languages
English (en)
Inventor
Uli Broedl
Afshin Salsali
Hans-Juergen Woerle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2018002532A1 publication Critical patent/CL2018002532A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS PARA PREVENIR O TRATAR INSUFICIENCIA CARDÍACA CRÓNICA O AGUDA Y PARA REDUCIR EL RIESGO DE MUERTE CARDIOVASCULAR, HOSPITALIZACIÓN POR INSUFICIENCIA CARDÍACA Y OTRAS AFECCIONES EN PACIENTES CON FRACCIÓN DE EYECCIÓN REDUCIDA O CONSERVADA MEDIANTE LA ADMINISTRACIÓN DE EMPAGLIFLOZINA AL PACIENTE.
CL2018002532A 2016-03-16 2018-09-05 Composición farmacéutica que comprende empagliflozina y sus usos CL2018002532A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309008P 2016-03-16 2016-03-16
US201662420062P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
CL2018002532A1 true CL2018002532A1 (es) 2019-01-04

Family

ID=58267120

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002532A CL2018002532A1 (es) 2016-03-16 2018-09-05 Composición farmacéutica que comprende empagliflozina y sus usos

Country Status (13)

Country Link
US (6) US20170266152A1 (es)
EP (1) EP3429595A1 (es)
JP (4) JP7161405B2 (es)
KR (6) KR20240095321A (es)
CN (4) CN118903166A (es)
AU (3) AU2017233889B2 (es)
BR (1) BR112018016001A2 (es)
CA (1) CA3017992A1 (es)
CL (1) CL2018002532A1 (es)
MA (1) MA43709A (es)
MX (4) MX2018011088A (es)
PH (2) PH12021552046A1 (es)
WO (1) WO2017157816A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP4684831A3 (en) 2009-02-13 2026-03-11 Boehringer Ingelheim International GmbH Sglt2 inhibitor for improving glycemic control
HUE050287T2 (hu) 2009-02-13 2020-11-30 Boehringer Ingelheim Int SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1215378A1 (zh) 2013-04-18 2016-08-26 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
AU2017357589B2 (en) 2016-11-10 2023-05-11 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN111163782A (zh) * 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
SG11202007172YA (en) 2018-06-06 2020-08-28 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
WO2020016335A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109846898A (zh) * 2019-02-01 2019-06-07 同济大学 恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
IT201900006624A1 (it) * 2019-05-08 2020-11-08 Moret Giannino Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4021507A1 (en) * 2019-08-30 2022-07-06 AstraZeneca AB Methods of treating heart failure with reduced ejection fraction with dapagliflozin
WO2021049612A1 (ja) * 2019-09-13 2021-03-18 国立大学法人富山大学 急性心不全における体液貯留改善薬
BR112022016360A2 (pt) * 2020-02-17 2022-10-04 Boehringer Ingelheim Vetmedica Gmbh Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
EP4376829A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
NZ598318A (en) * 2009-09-30 2014-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) * 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1215378A1 (zh) * 2013-04-18 2016-08-26 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途

Also Published As

Publication number Publication date
MX2021010329A (es) 2021-10-13
PH12021552046A1 (en) 2022-06-27
US20180318251A1 (en) 2018-11-08
US20250073200A1 (en) 2025-03-06
KR20230028565A (ko) 2023-02-28
CA3017992A1 (en) 2017-09-21
JP2023001136A (ja) 2023-01-04
MX2018011088A (es) 2018-11-22
AU2017233889B2 (en) 2022-07-07
WO2017157816A1 (en) 2017-09-21
US20220211659A1 (en) 2022-07-07
KR20230028568A (ko) 2023-02-28
CN118286238A (zh) 2024-07-05
BR112018016001A2 (en) 2018-12-18
KR20250161667A (ko) 2025-11-17
MX2024005626A (es) 2024-05-24
JP2019508453A (ja) 2019-03-28
JP2024083347A (ja) 2024-06-21
EP3429595A1 (en) 2019-01-23
US20210059974A1 (en) 2021-03-04
AU2017233889A1 (en) 2018-08-09
AU2024216447A1 (en) 2024-09-19
CN118903166A (zh) 2024-11-08
MX2022008491A (es) 2022-08-02
KR20240095321A (ko) 2024-06-25
JP2021181461A (ja) 2021-11-25
JP7161405B2 (ja) 2022-10-26
PH12018501969A1 (en) 2019-06-17
KR20230111262A (ko) 2023-07-25
KR20180122004A (ko) 2018-11-09
CN118286237A (zh) 2024-07-05
US20190350894A1 (en) 2019-11-21
MA43709A (fr) 2018-11-28
AU2022246392A1 (en) 2022-10-27
CN109069525A (zh) 2018-12-21
US20170266152A1 (en) 2017-09-21
AU2022246392B2 (en) 2024-09-19
JP7454531B2 (ja) 2024-03-22

Similar Documents

Publication Publication Date Title
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CL2019000266A1 (es) Composición de cannabis.
IL257379A (en) Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex
ECSP17021754A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
UY36550A (es) Oligómeros antisentido de tau y sus usos
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
CL2018003489A1 (es) Composición y método para reducir neutropenia
CL2017001046A1 (es) Inhibidoes del bromodominio
GT201500011A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
ECSP19077969A (es) Compuesto heterociclico
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
BR112018069927A2 (pt) terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
MX377211B (es) Composiciones terapéuticas para usarse en el tratamiento del cáncer.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
BR112017021190A2 (pt) composição farmacêutica e o uso da mesma
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
MD20180049A2 (ro) Compoziţie farmaceutică